Moderna responds to concerns surrounding its Covid-19 vaccine trial data

Moderna’s chairman is standing by the company’s data on its potential coronavirus vaccine. The chairman’s comments are in response to a report that raised a number of questions about the early-stage trial results and led to a volatile few days for the stock. CNBC’s Meg Tirrell reports.